Changes in thyroid function tests are generally not observed, despite theoretical concerns based on animal studies showing thyroid C-cell effects
hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
Important Safety Information: If pregnant or nursing, consult your healthcare provider before use
(6) Studies have documented that NNMT is highly expressed in white adipose tissue and that its expression correlates with obesity in both humans and animal models
Modest metabolic benefits: Some studies have shown small benefits like a slight decrease in LDL cholesterol, but these effects dont persist after discontinuation